Gilmartin Capital announced today that it launched its first venture fund, to be led by medtech industry expert David Lewis.
The Gilmartin Capital Fund I will focus on investment opportunities in the medical device, life science tools, diagnostics and digital health sectors, Gilmartin said in a news release.
Lewis is the founder and managing partner of Gilmartin Capital. He has spent 25 years in medtech advising investors, companies and boards on strategic and financial direction, including the last 15 years as a managing director at Morgan Stanley, where he led the firm’s technology equity research practice.
He said the COVID-19 pandemic catalyzed the importance of acute care medical devices, tools for driving therapeutic discovery and the need for remotely managing patients, and that he believes the San Francisco-based venture firm is well positioned to deploy capital intelligently across the expanding markets.
“The launch of Gilmartin Capital is the culmination of my passion for healthcare technology and decades of experience as an analyst,” Lewis said in the news release. “I am enthusiastic that our first close is meaningfully oversubscribed with a limited partner group comprised predominantly of executives, operators and scientific thought leaders spanning the healthcare sector. Our strategy is to avail our experience and network to help innovators solve problems, drive scientific discovery, help patients and generate outsized returns for our investors.”